Crinecerfont
Crenessity (crinecerfont) is an oral prescription capsule medication manufactured by Neurocrine Biosciences, Inc. It acts as a corticotropin-releasing factor type 1 receptor antagonist, available in 25mg, 50mg, and 100mg strengths. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Crenessity (crinecerfont) is an oral prescription capsule medication manufactured by Neurocrine Biosciences, Inc. It acts as a corticotropin-releasing factor type 1 receptor antagonist, available in 25mg, 50mg, and 100mg strengths. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Crinecerfont",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Crinecerfont — ANDA 218808 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218808"
}
]
|
| identifier | ANDA218808 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-information",
"fda",
"health-care",
"prescription-drugs"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Crinecerfont |
